ClinicalTrials.gg

Program

HS-10390

A development code. Also written as “HS-10390 tablet”.

Its studies are mostly in Glomerulonephritis, IGA · Renal Insufficiency, Chronic, led by Hansoh Pharmaceutical Group.

Furthest: phase 2, since Oct 8, 20243 company-led studies, 3 open or runningNext primary completion: Nov 11, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hansoh Pharmaceutical Group33 open or runningphase 2since Oct 8, 2024Jul 4, 2023Nov 11, 2027phase 2 · NCT07555054

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 4, 2023First study: phase 1 study in Glomerulonephritis, IGAFirst studyNCT05942625 · 84 planned · China
  2. Oct 8, 2024Phase 2 study in Glomerulonephritis, IGANCT06635772 · 90 planned · China
  3. Apr 21, 2026Phase 2 study in Renal Insufficiency, ChronicNCT07555054 · 182 planned · China

Ahead

  1. Nov 11, 2027Primary completion: phase 2 study in Renal Insufficiency, ChronicNCT07555054

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07555054Renal Insufficiency, Chronic · China2Not yet recruitingNov 11, 2027182
NCT06635772Glomerulonephritis, IGA · China2Not yet recruitingDec 1, 202590
NCT05942625Glomerulonephritis, IGA · China1RecruitingJun 30, 202484

How it is read

Names in the registry

  • “HS-10390”, 4 entries
  • “HS-10390 tablet”, 1 entry

Codes read as this program: HS10390.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.